Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York from September 3-5, 2025. The company's CEO, Daniel Passeri, will present on September 5, 2025, at 8:00 a.m. EDT.
During the presentation, the company will discuss updates on their Immuno-STAT® platform and the development progress of CUE-401, their primary autoimmune treatment candidate. The presentation will be available via webcast and archived for 30 days on the company's website.
Cue Biopharma (Nasdaq: CUE), azienda biofarmaceutica in fase clinica, parteciperà a un fireside chat al Cantor Global Healthcare Conference a New York dal 3 al 5 settembre 2025. L’amministratore delegato, Daniel Passeri, interverrà il 5 settembre 2025 alle 8:00 EDT.
Durante l’intervento verranno fornite aggiornamenti sulla piattaforma Immuno-STAT® e sullo stato di sviluppo di CUE-401, il loro principale candidato per il trattamento delle malattie autoimmuni. La presentazione sarà trasmessa in streaming e rimarrà archiviata per 30 giorni sul sito web della società.
Cue Biopharma (Nasdaq: CUE), una compañía biofarmacéutica en fase clínica, participará en una charla tipo "fireside" en la Cantor Global Healthcare Conference en Nueva York del 3 al 5 de septiembre de 2025. El director ejecutivo, Daniel Passeri, presentará el 5 de septiembre de 2025 a las 8:00 a.m. EDT.
Durante la presentación se hablará de las novedades de la plataforma Immuno-STAT® y del progreso en el desarrollo de CUE-401, su principal candidato para el tratamiento de enfermedades autoinmunes. La presentación se podrá ver por webcast y quedará archivada durante 30 días en la web de la compañía.
Cue Biopharma (Nasdaq: CUE)는 임상 단계의 바이오제약회사로서 2025년 9월 3일부터 5일까지 뉴욕에서 열리는 Cantor Global Healthcare Conference의 파이어사이드 채팅에 참가합니다. 최고경영자 다니엘 패세리(Daniel Passeri)는 2025년 9월 5일 오전 8시(EDT)에 발표할 예정입니다.
발표에서는 Immuno-STAT® 플랫폼에 대한 최신 정보와 주요 자가면역 질환 치료 후보물질인 CUE-401의 개발 진행 상황을 설명합니다. 발표는 웹캐스트로 제공되며 회사 웹사이트에 30일간 아카이브됩니다.
Cue Biopharma (Nasdaq: CUE), une société biopharmaceutique en phase clinique, participera à un fireside chat lors de la Cantor Global Healthcare Conference à New York du 3 au 5 septembre 2025. Le directeur général, Daniel Passeri, interviendra le 5 septembre 2025 à 8h00 EDT.
Lors de la présentation, la société fera le point sur sa plateforme Immuno-STAT® et l’avancement du développement de CUE-401, son principal candidat thérapeutique contre les maladies auto-immunes. La présentation sera diffusée en webcast et archivée pendant 30 jours sur le site web de la société.
Cue Biopharma (Nasdaq: CUE), ein biopharmazeutisches Unternehmen in klinischer Entwicklung, wird an einem Fireside-Chat auf der Cantor Global Healthcare Conference in New York vom 3. bis 5. September 2025 teilnehmen. Der CEO Daniel Passeri wird am 5. September 2025 um 8:00 Uhr EDT präsentieren.
In der Präsentation wird das Unternehmen Aktualisierungen zur Immuno-STAT®-Plattform und zum Entwicklungsfortschritt von CUE-401, ihrem führenden Kandidaten zur Behandlung von Autoimmunerkrankungen, vorstellen. Die Präsentation wird per Webcast verfügbar sein und für 30 Tage auf der Unternehmenswebsite archiviert.
- None.
- None.
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Cantor Global Healthcare Conference being held in New York, September 3-5, 2025.
During the fireside chat, Cue Biopharma will discuss program updates from the Immuno-STAT® platform including continued advancements in the development of CUE-401, the Company’s lead autoimmune asset.
Presentation Details
Cantor Global Healthcare Conference
Date: Friday, September 5, 2025
Time: 8:00 a.m. – 8:30 a.m. EDT
Presenter: Daniel Passeri, Chief Executive Officer
Webcast Link: https://stream.onstreammedia.com/onsm/GetReport?customerId=22&eventId=15390931
A live and archived webcast of the fireside chat will be available under News and Events in the News and Publications section of the Company’s website. The webcast will be archived for 30 days.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.
For more information, please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
FAQ
When is Cue Biopharma (CUE) presenting at the Cantor Global Healthcare Conference 2025?
Who will be presenting for Cue Biopharma at the Cantor Conference?
What topics will Cue Biopharma discuss during their Cantor Conference presentation?
How can investors access Cue Biopharma's Cantor Conference presentation?
